Open AccessIssue Information
Publication year - 2019
Publication title -
molecular oncology
Language(s) - English
Resource type - Reports
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12342
Subject(s) - citation , doxorubicin , calreticulin , cd47 , cancer , library science , medicine , cancer research , political science , oncology , computer science , phagocytosis , chemistry , immunology , biochemistry , chemotherapy , endoplasmic reticulum
Additive therapeutic efficacy of CD47mAb and doxorubicin therapy: CD47mAb blocks a ‘don't eat me’ signal (CD47) on cancer cells and doxorubicin causes expression of an ‘eat me’ signal (calreticulin) on cancer cells, leading to highly effective macrophage phagocytosis. Image created by Jim Strommer, Stanford University. See article by Mohanty et al. (pp 2049–2061).